Hagens Berman says GeneDx investors have until Aug. 3 to seek lead plaintiff status
Hagens Berman says a securities fraud class action has been filed against GeneDx Holdings Corp. and that investors who bought GeneDx common stock during the stated class period may seek lead plaintiff status by Aug. 3, 2026.
Hagens Berman Sobol Shapiro LLP says a securities fraud class action has been filed against GeneDx Holdings Corp. and is urging investors who bought the company’s common stock between April 16, 2025, and May 4, 2026, and suffered losses to seek lead plaintiff status by Aug. 3, 2026.
The notice sets a deadline for investors who say they were harmed to ask the court to represent the proposed class. It also identifies the period the firm says is at issue and the stock drop it ties to GeneDx’s May 4, 2026, earnings release.
According to the PR Newswire alert, GeneDx reported first-quarter 2026 financial results after the market closed on May 4, 2026. The release says WGS shares fell 49.2% in a single session, from a close of $67.93 to $34.51, on heavy trading volume.
The alert says the complaint centers on management’s statements about the integration of Fabric Genomics and claimed AI-driven efficiencies. It says those statements misled investors, though the notice does not include a court ruling on the claims.
Reed Kathrein, the Hagens Berman partner leading the firm’s investigation, said in the release that the complaint alleges investors were misled by management’s positive statements regarding the Fabric Genomics integration and its supposed AI-driven efficiencies.
The notice also says the alleged class period runs from April 16, 2025, through May 4, 2026. It tells investors with substantial losses to contact the firm and says SEC whistleblowers with original information may be eligible for rewards of up to 30% of any successful SEC recovery.
Hagens Berman also says on its notice that its team has secured more than $2.9 billion in this area of law. The firm’s alert provides contact information for Reed Kathrein.
The Aug. 3 lead plaintiff deadline named in the notice is the next step. Investors who believe they are eligible must ask the court by then to appoint them as lead plaintiff.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
Comments ()